secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUPERNUS PHARMACEUTICALS, INC. (SUPN)
CIK:        0001356576
Form:       8-K
Filed at:   2026-02-12T23:59:59+00:00
Accession:  0001356576-26-000002
Event type: earnings
Sentiment:  neutral
Materiality: 0.20
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Supernus schedules Q4 2025 earnings release for Feb 24, 2026 after market close
-------------------------------------------------------------------------------

- Q4 and full year 2025 results to be reported after market close on February 24, 2026.
- Conference call and webcast at 4:30 p.m. ET on February 24, 2026, hosted by CEO Jack Khattar and CFO Tim Dec.
- No preliminary financial results or guidance provided in the announcement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356576/000135657626000002/0001356576-26-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356576/000135657626000002/supn-20260212.htm
  HTML page:      https://secwatch.observer/filing/0001356576-26-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer